Media headlines about Pernix Therapeutics (NASDAQ:PTX) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pernix Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 46.7926282122374 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Pernix Therapeutics traded up $0.01, reaching $2.36, during trading on Friday, according to MarketBeat. The stock had a trading volume of 64,900 shares, compared to its average volume of 108,782. Pernix Therapeutics has a fifty-two week low of $2.00 and a fifty-two week high of $5.18. The company has a quick ratio of 0.82, a current ratio of 0.88 and a debt-to-equity ratio of -1.45.
Pernix Therapeutics (NASDAQ:PTX) last issued its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported ($1.57) earnings per share for the quarter. The firm had revenue of $28.14 million during the quarter.
Separately, ValuEngine raised Pernix Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
Pernix Therapeutics Company Profile
Pernix Therapeutics Holdings, Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry.
Receive News & Ratings for Pernix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.